Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14258531 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22862014 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL26315916 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL18591853 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL18365026 | 1.00 | TDP1 (0.50) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL10072751 | 0.98 | TDP1 (0.51) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL12885084 | 0.93 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22276641 | 0.93 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL22276648 | 0.93 | TDP1 (0.56) | TDP1MEN1KMT2AGAACA12 | |
| SCHEMBL29975063 | 0.91 | CA12 (0.46) | TDP1MEN1KMT2AGAACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120590466-B | Compound of targeted fibroblast activation protein and application thereof | 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) | 2026-05-12 | — | — | CN | disclosed |
| CN-118451078-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023249968-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-117203196-A | PDE4 degrading agents, pharmaceutical compositions and therapeutic applications | 拜欧斯瑞克斯公司 | 2023-12-08 | — | — | CN | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-109415336-B | MDM2 protein degradation agent | 密执安大学评议会 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022140472-A1 | COMPOUNDS FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEOSOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2022081984-A1 | METHODS AND COMPOUNDS TO TREAT SARS INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2016113168-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | disclosed |
| US-9353150-B2 | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160096920-A1 | PROCESS FOR THE PREPARATION OF AN OBJECT SUPPORTING A LIPID BILAYER | LIPOCOAT IP HOLDING B.V. (NL) | 2016-04-07 | — | — | US | disclosed |
| US-9084826-B2 | Fatty acid conjugates of statin and FXR agonists; compositions and method of uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8877171-B2 | Polyanionic multivalent macromolecules for intracellular targeting of proliferation and protein synthesis | MIVENION GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20140187500-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130095035-A1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | MIVENION GMBH (DE) | 2013-04-18 | — | — | US | disclosed |
| WO-2012062910-A1 | ISOLATION AND FUNCTIONAL IDENTIFICATION OF CELLS | CAPROTEC BIOANALYTICS GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012006475-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2010126914-A1 | PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS | ELAN PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095035-A1 | POLYANIONIC MULTIVALENT MACROMOLECULES FOR INTRACELLULAR TARGETING OF PROLIFERATION AND PROTEIN SYNTHESIS | MKI67, PCNA, ACP1 | TDP1 3834/4885MEN1 2735/4885KMT2A 3667/4885 |
| US-20140187500-A1 | COMPOUNDS, CONJUGATES AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES | DNPEP, NPEPPS, PIN1 | TDP1 2703/4885MEN1 1381/4885KMT2A 621/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TDP1 236/4885MEN1 4055/4885KMT2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.